Flexion Therapeutics is an American pharmaceutical company based in Burlington, Massachusetts that is developing reformulated sustained release versions of existing drugs that are intended to be injected into the joint to treat osteoarthritis.It was founded around 2007 by two former Eli Lilly & Co. executives and went public in 2014.In November 2016 the FDA accepted Flexion's New Drug Application for FX006, a sustained-release formulation of triamcinolone acetonide (a corticosteroid), branded "Zilretta".
Burlington, MA, United States.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Flexion Therapeutics is implementing good security practices.
Read more about the latest issues in cybersecurity
A cyber attack (or cyberattack) is any attempt to expose, alter, disable, destroy, steal or gain ...
The Domain Name System Security Extensions (DNSSEC or DNS Security Extensions) is a set of Internet ...
Compare Flexion Therapeutics's security performance with other companies